Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review

The objective was to determine the clinical and economic burden of AF in onco-hematological patients in Europe.AREAS COVERED: A targeted literature review was completed for observational, retrospective and case studies, and reviews on AF in onco-hematology published between January 2010 and 2022 in PubMed, Science Direct, Medes, and IBECS. The search was based on epidemiology, costs, health-related quality of life (HRQoL), disease burden and management, and patient journey. Thirty-one studies fulfilled eligibility criteria. Annual incidence of AF during treatment varies up to 25%, and has increased with first-generation Bruton tyrosine kinase inhibitors (BTKi). Risk factors include age ≥ 65, prior AF or hypertension, hyperlipidemia and ibrutinib use. AF-related complications are managed with anticoagulants and/or antiarrhythmics, and regular monitoring. When AF is no longer controllable, dose reduction or treatment discontinuation is recommended. No data on costs, HRQoL and patient journey were identified.EXPERT OPINION: There is scarce and heterogeneous information on AF in onco-hematology in Europe. Available evidence reports a higher risk of AF associated with first-generation BTKi. Further studies are needed to understand the burden of AF in these patients.PMID:37306506 | DOI:10.1080/17474086.2023.2223926
Source: Expert Review of Hematology - Category: Hematology Authors: Source Type: research